Company

Location

Date

Amt. (M)

Details

Aegerion
Pharmaceuticals
Inc.

Bridgewater, N.J.

3/22

Aegerion entered into a $15M loan and security agreement with Hercules Technology Growth Capital Inc.; it expects to use proceeds from an IPO to repay the outstanding amount

Aerovance Inc.

Berkeley, Calif.

3/27

$32

Aerovance raised $32M in a second tranche of a Series C financing that began a year ago with a $28M raise; new investor Clarus Ventures led the round and was joined by Alta Partners, Apax Partners, Lehman Brothers, NGN Capital and Burrill & Co.

Affinium
Pharmaceuticals
Inc.

Toronto

3/26

$18

Affinium raised $18M in a Series A led by Forward Ventures, with participation from Oxford Bioscience Partners and SV Life Sciences and existing investor Genesys Capital

Alacrity
Biosciences
Inc.

Laguna Hills, Calif.

3/2

$8.4

Alacrity raised $8.4M, which should take it through the third quarter when the company plans to conduct a Series A round

Amira
Pharmaceuticals
Inc.

San Diego

3/23

$25

Amira raised $25M in a Series B round, which included investments from Versant, Avalon Ventures and Prospect Venture Partners

AutoGenomics
Inc.

Carlsbad, Calif.

3/28

$12

AutoGenomics completed a $12M Series C round with investments coming primarily from non-institutional investors

Axial Biotech

Salt Lake City

3/27

$15.3

Axial raised $15.3M in a Series B round led by Johnson and Johnson Development Corp.; other investors were vSpring Capital and Ohio Biotech Group LLC

Calistoga
Pharmaceuticals

Seattle

3/5

$21

Series A round was led by Frazier Healthcare Ventures; other investors were Alta Partners, Three Arch Partners and Amgen Ventures

Celegos*
(subsidiary of
HRA Pharma;
France)

Paris

3/7**

€2.5($3.27)

Celogos raised $3.27M through an investment from parent company HRA Pharma

Cylex Inc.

Columbia, Md.

3/6

$2.1

Cylex raised another $2.1M in its third round, bringing the total amount raised to $20.5M

Cytochroma
Inc.

Markham, Ontario

3/29

$3

Cytochroma secured $3M from the Canadian Medical Discoveries Fund Inc. and University Medical Discoveries Inc.

Endocyte
Inc.

West Lafayette, Ind.

3/23

$15

Endocyte raised $15M in a Series C-3 round, which included investments from Sanderling Venture Partners, Burrill & Co., Triathlon Venture Partners, Blue Chip Venture Co., American Bailey Ventures and CID Capital

Epiphany
Biosciences
Inc.

San Francisco

3/15

$36

The Series A financing round was led by Wexford Capital LLC and included Windsor Bay Capital LLC, Global Trust Ventures Management LLC, CDIB BioScience Venture Management and several private investors

EUSA Pharma
Inc.

New York

3/1

$175

EUSA launched with a $175M private financing from Essex Woodland, Goldman Sachs, Advent Venture Partners, NeoMed and NovaQuest

Intarcia
Therapeutics
Inc.

Emeryville, Calif.

3/19

$50

New Leaf Venture Partners led the Series B financing round; also participating were Quilvest Ventures, another new investor, and existing investors New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund and Granite Global Ventures

MAP
Pharmaceuticals
Inc.

Mountain View, Calif.

3/28

$50

MAP brought in $50M in its Series D round with investments from D.E. Shaw group and all previous investors, including the Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital, Bay City Capital and Skyline Ventures

Microbia Inc.

Cambridge, Mass.

3/1

$50

Microbia raised $50M in a financing led by Ridgeback Capital; it also included investments from Morgan Stanley Investment Management, as well as existing investors

Nitec Pharma
AG

Basel, Switzerland

3/29

CHF32
($26)

Nitec closed a $26M Series B led by NGN Capital; it included investments from Atlas Venture and Global Life Science Ventures

Numira
Biosciences

Irvine, Calif.

3/21

$2.5

Numira secured $2.5M in its Series A round led by vSpring Capital; it included participation from the Tech Coast Angels and the Pasadena Angels

PainCeptor
Pharma Corp.

Montreal

3/6

C$24.4 ($20.7)

PainCeptor raised $20.7M through a Series B round; investors were Desjardins Venture Capital, CDP Capital, T2C2/Bio 2000, Business Development Bank of Canada and Lothian Partners 27 SICAR

Phenomix Corp.

San Diego

3/7

$55

Phenomix raised $55M in the Series C round led by Nomura Phase4 Ventures; other investors were JP Morgan Partners, Delphi Ventures, Alta Partners, Sofinnova Ventures, Bay City Capital, CMEA Ventures, Baker Brothers, Novartis BioVenture Fund and GBC Venture Partners

Potentia
Pharmaceuticals
Inc.

Louisville, Ky.

3/7

$5

Potentia closed a $5M round with private investors

ProFibrix BV

Leiden, the Netherlands

3/28**

€8.5 ($11.3)

ProFibrix raised $11.3M in a Series A round led by Index Ventures

Regado
Biosciences Inc.

Durham, N.C.

3/27

$23

Regado raised $23M in a Series C round led by Caxton Advantage Life Sciences Fund, Domain Associates and Quaker BioVentures; Aurora Funds and individuals also participated

Spaltudaq
Corp.

Seattle

3/16

$29

The Series B financing was led by ARCH Venture Partners, Canaan Partners and Healthcare Ventures; also participating were Amgen Ventures, MPM Capital and Alexandria Equities LLC

Tragara
Pharmaceuticals
Inc.

San Diego

3/14

$40

Investing in the Series A financing were Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners and Mitsubishi International Corp.

TransOral
Pharmaceuticals
Inc.

Port Richmond, Calif.

3/6

$40

TransOral raised $40M in a Series D round led by New Enterprise Associates; other investors were New Leaf Venture Partners, Montreux Equity Partners, InterWest Partners, Hamilton Bio- Ventures, Vivo Ventures and Peninsula Equity Partners

VentiRx
Pharmaceuticals
Inc.

San Diego

3/5

$26.6

The Series A round was co-led by Frazier Healthcare Ventures, ARCH Venture Partners and Domain Associates

Zogenix Inc.

San Diego

3/19

$3.5

Zogenix received $3.5M of a $10M loan facility with GE Healthcare Financial Services; terms of the deal were not disclosed